发明名称 |
Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia |
摘要 |
The method of using nutritional compounds including Dihydroquercetin (taxifolin). Arabinogalactan and Arabinogalactan combined with Dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors, associated with metabolic syndrome and hypercholesterolemia in a mammal, specifically a human, resulting in the enhancement of metabolism, reduced control levels of cholesterol and triglycerides, reduced oxidative damage in humans and other health benefits. |
申请公布号 |
US8962594(B2) |
申请公布日期 |
2015.02.24 |
申请号 |
US201414257162 |
申请日期 |
2014.04.21 |
申请人 |
Flavitpure, Inc. |
发明人 |
Philippov Sergey V.;Bogorodov Igor M. |
分类号 |
A61K31/717;A61K31/353;A61K31/352;A61K31/715;A23L1/30;A23L2/52 |
主分类号 |
A61K31/717 |
代理机构 |
|
代理人 |
Vishev Anna |
主权项 |
1. A method of using nutritional compounds for lowering triglycerides and increasing HDL-cholesterol in humans, the method comprising the steps of:
identifying a particular human who has high triglycerides and low HDL-cholesterol by determining whether said particular human has a triglyceride level greater than 150 mg/dl, whether said particular human has an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women, and whether said particular human has at least one characteristic selected from the group consisting of: (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women, (b) a blood pressure greater than or equal to 130/85 mmHG, and (c) a fasting glucose level greater than 110 mg/dl; and administering internally a nutritional compound comprising a combination of an Arabinogalactan and a Dihydroquercetin (taxifolin), said Arabinogalactan being present in said combination as a fiber matrix in an amount higher than 70% as determined by weight on a dry matter basis, and said Dihydroquercetin being present in said fiber matrix, such that, after said internal administration of said nutritional compound, said particular human has a triglyceride level of less than 150 mg/dl, has an HDL-cholesterol level greater than 40 mg/dl for men and greater than 50 mg/dl for women, and no longer has the at least one characteristic selected from the group consisting of (a), (b), and (c). |
地址 |
Cheyenne WY US |